BlackRock
RVLP

BlackRock’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

BlackRock’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-225,727
Closed -$19.5K – 5534
2023
Q3 		$19.5K Sell
225,727
-6,114
-3% -$1.76K ﹤0.01% 5148
2023
Q2 		$130K Buy
231,841
+18,304
+9% +$16.1K ﹤0.01% 4841
2023
Q1 		$243K Buy
213,537
+10,895
+5% +$13.1K ﹤0.01% 4723
2022
Q4 		$227K Buy
202,642
+1,223
+0.6% +$1.95K ﹤0.01% 4816
2022
Q3 		$423K Sell
201,419
-5,759
-3% -$11.2K ﹤0.01% 4772
2022
Q2 		$282K Sell
207,178
-5,009
-2% -$7.25K ﹤0.01% 4943
2022
Q1 		$358K Buy
212,187
+54,315
+34% +$77.7K ﹤0.01% 4960
2021
Q4 		$172K Sell
157,872
-12,630
-7% -$20.5K ﹤0.01% 5139
2021
Q3 		$503K Buy
170,502
+3,252
+2% +$10.9K ﹤0.01% 4750
2021
Q2 		$503K Sell
167,250
-1,150,685
-87% -$3.52M ﹤0.01% 4696
2021
Q1 		$4.3M Sell
1,317,935
-2,249
-0.2% -$9.25K ﹤0.01% 4008
2020
Q4 		$5.44M Sell
1,320,184
-21,115
-2% -$122K ﹤0.01% 3670
2020
Q3 		$7.26M Sell
1,341,299
-47,624
-3% -$274K ﹤0.01% 3407
2020
Q2 		$9.35M Buy
1,388,923
+261,086
+23% +$1.28M ﹤0.01% 3216
2020
Q1 		$3.59M Buy
1,127,837
+48,311
+4% +$257K ﹤0.01% 3477
2019
Q4 		$7.54M Buy
1,079,526
+605,048
+128% +$3.23M ﹤0.01% 3378
2019
Q3 		$1.82M Buy
474,478
+34,267
+8% +$116K ﹤0.01% 3782
2019
Q2 		$1.67M Sell
440,211
-18,001
-4% -$59.8K ﹤0.01% 3837
2019
Q1 		$1.65M Sell
458,212
-16,867
-4% -$124K ﹤0.01% 3771
2018
Q4 		$3.68M Buy
+475,079
New +$3.8M ﹤0.01% 3488

Other funds holding RVLP

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BlackRock's RVLP Position: Q4 2023 in Review

BlackRock sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 225,727 shares — an estimated $19.5K sold.

BlackRock first reported a position in RVLP in Q4 2018 and held it in 20 quarters. The position peaked at $9.35M in Q2 2020. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

  • BlackRock reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 225,727 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023, an estimated $19.5K.
  • BlackRock first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 20 quarters.
  • BlackRock's RVL Pharmaceuticals plc Ordinary Shares position peaked at $9.35M in Q2 2020.
  • 3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.